G6PD and neoplasm: Increased activity of G6PD/PPP, which is frequently observed in various tumors, enhances the production of NADPH, which might decrease tumor cell drug sensitivity towards DNA-damage-based anti-tumor drugs such as oxaliplatin, doxorubicin, and daunorubicin [70,144,161,162].